SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Stressgen (VSE: SSB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Heat Shock who wrote (196)8/15/2002 5:45:58 PM
From: Heat Shock  Read Replies (1) of 236
 
To all: Stressgen, Roche and hepatitis C.

Stressgen's press releases have a sentence like this: "Stressgen has a program to evaluate Hsp fusions in hepatitis B and has initiated research studies to evaluate its Hsp fusion technology in the treatment of herpes simplex and HIV." Starting around July, they have been adding hepatitis C to the list with herpes simplex and HIV.

Stressgen's HspE7 collaboration partner, Roche, has a new hepatitis C treatment.

From Roche.com, << “Our shared commitment with the scientific, medical and patient communities has been to halt the progression of this pandemic disease, which until now has posed an enormous clinical challenge,” said William Burns, Head of Pharmaceuticals Division, Roche. “With Pegasys we have achieved a major scientific and technological breakthrough in treating hepatitis C infection. Roche will continue its cutting-edge research and development activities in this area and provide next generation treatment concepts.” >>

Heat.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News